Literature DB >> 19571293

Cetuximab for metastatic colorectal cancer.

Howard Spiro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19571293     DOI： 10.1056/NEJMc090927

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Low clinical adoption of tumor genomic profiling: cause for concern?

Authors:  Michael W Drazer; Randy F Sweis
Journal:  J Med Econ       Date:  2018-05-15       Impact factor: 2.448

Review 2.  Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity.

Authors:  Steve C Lee; Raghvendra M Srivastava; Andrés López-Albaitero; Soldano Ferrone; Robert L Ferris
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

Review 3.  Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity.

Authors:  Sumita Trivedi; Hyun-Bae Jie; Robert L Ferris
Journal:  Semin Oncol       Date:  2014-08-12       Impact factor: 4.929

Review 4.  Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.

Authors:  Robert L Ferris; Elizabeth M Jaffee; Soldano Ferrone
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.